7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip

Vertex Pharmaceuticals (NASDAQ: VRTX) reported its second-quarter results, leading to a more than 17% drop in shares during early trading on Tuesday, despite the results not being poor overall. The negative investor reaction stemmed from two disappointing developments in its pipeline, which may present buying opportunities for some investors.

Want More Context? 🔎